AQEMIA

🌟 Sanofi x AQEMIA: Redefining the way new medicines are developed, atom by atom 🌟 Together, we aim to redefine the way new medicines are developed, accelerating the delivery of innovative treatments to patients. By combining Sanofi’s R&D expertise with AQEMIA’s physics-powered algorithms, our partnership is pioneering the design and optimization of molecules with unparalleled speed and precision. In this conversation, Matt Truppo (Sanofi’s Global Head of Research Platforms & Computational R&D) and Maximilien Levesque (AQEMIA CEO & Cofounder) discuss how this unique collaboration is accelerating progress in drug discovery. Watch the full discussion below ⤵ #Biotech #GenAI #DrugDiscovery

{Press Review} : AI Feature for l'Opinion : the 100 who are powering AI in Europe In an interview with l'Opinion, AQEMIA's co-founder and COO, Emmanuelle Martiano Rolland, shared insights into our mission to combine generative AI with theoretical physics in the quest for breakthrough cancer treatments. The article also highlights our partnership with Sanofi and how our technology is already showing promising results in preclinical studies. While we’re proud of our French roots 🇫🇷 , our mission is global: advancing research and therapies to benefit patients worldwide 🌎 Thank you l'Opinion and Grégoire Arnould-Cordier for this insightful conversation ⤵  https://lnkd.in/e7eKcRVu #AI #DrugDiscovery #Biotech #Healthcare #lOdysseedelIA

Bravo La French Tech ! Hier soir était la rentrée de la Mission French Tech, avec la belle annonce par la secrétaire d’Etat chargée de l’Intelligence artificielle et du Numérique Clara Chappaz, de celle qui lui succède à ce poste : Julie Huguet. J'ai eu l'honneur d'être invité à la table ronde qui a suivi l'annonce, avec Julie et Anne Vincent-Salomon (Institut Curie) et animée par Charlie Perreau de Les Echos. On a parlé des ponts entre la recherche et entrepreneuriat, donc de #deeptech, d' #IA … et de souveraineté, cette souveraineté positive, celle de l'investissement en soi et en les autres, celle de la construction des champions de demains, de la compétition par le dépassement de soi et l'exploration de l'inconnu (de la recherche ! 😇). J'étais très heureux d'être parmi vous. Merci Lucie Finet pour ton invitation et toute la French Tech pour votre optimisme et votre confiance.

💊 Comment l'IA va-t-elle influer sur la recherche médicamenteuse ? Comment le secteur de l'industrie pharmaceutique va-t-il devoir se réinventer ? Quel rôle #startups et grands groupes jouent-ils ensemble sur ces sujets pour accélérer l'#innovation et la recherche ? 💡 Ce sont les questions posées par le 5e épisode de notre série d'événements Les Tech'Up du Hub 💬 Au programme, des invités de choix issus des métiers IT et pharma avec : - une keynote de Vivien Londe, Senior Software Engineer chez Microsoft France - une table-ronde incluant un grand groupe et deux participations Bpifrance Large Venture : - Hervé Minoux, Head of AI for Large Molecule Research chez Sanofi - Maximilien Levesque, CEO et co-founder d'AQEMIA - Alban de La Sablière, Chief Operating Officer d'Owkin Retrouvez dans cet article de Big Media les insights à conserver de cet événement 👇 https://lnkd.in/dq-AUGnh Voir également le replay 👉 https://lnkd.in/ezxjBt9b Pour aller + loin, visionnez l'intervention plébiscitée de Vivien Longue sur la chaîne Youtube "Underscore_" 👉 https://lnkd.in/e7iug55a #pharma #IA #AI #tech Maïlys Ferrere Laurent Higueret Marine Choplain Mathilde Lairet Emilie Beckmann Estelle BASTO LOISANCE Alexia Guittard Sofia Ben Dhaya

Today, we’re giving you a behind-the-scenes look at our team’s experience last week at #RICT2024, the International Conference on Medicinal Chemistry held in Bordeaux, focusing on 'Interfacing Chemical Biology and Drug Discovery.' Congratulations to Nicolas George for being invited to chair two sessions: Next Generation Cancer Therapeutics, and First Disclosures of Clinical Candidates and Case Studies, where a potent and selective antagonist of CCR6 was disclosed, alongside novel c-MET inhibitors 🧬. There were in particular some leading talks on PROTACs and computational strategies to design RNA-targeting small molecules, tackling the highly flexible and elusive nature of RNA targets . At AQEMIA, we are excited to be at the forefront of combining generative AI with deep physics and medicinal chemistry to discover new drugs for unmet medical needs 💊 . A big thank you to the other team members who were also present at the event: Salete Baptista, Alessio Prunotto, Piermichele Kobauri 🌟 #DrugDiscovery #MedicinalChemistry #MachineLearning #Biotech #AQEMIA #CancerTherapeutics cc Société de Chimie Thérapeutique SCT

Maddyness et Banque Richelieu s'associent pour présenter la sélection des 50 personnalités influentes et prometteuses sur l'Intelligence Artificielle. 🙌 Place à la présentation de nos 5 premiers profils sélectionnés de la #MAD50 spéciale IA ! 🤖 - Charles Gorintin, co-fondateur et CTO d'Alan - Emmanuelle Martiano Rolland, co-fondatrice et COO de AQEMIA - Arthur Mensch, co-fondateur et CEO de Mistral AI - Aude Durand, Directrice Générale Déléguée du Groupe iliad. - Séverine Grégoire, Head of AI Department de CMA CGM. Découvrez l'ensemble des profils sélectionnés : https://lnkd.in/eutqVNc4 - en partenariat avec Banque Richelieu 🌟 Merci également à nos partenaires Raise, France FinTech et France Digitale.

🌟 Welcome to The Jungle 🌟 Ever wondered what it is like to be a Drug hunter or a Software engineer at AQEMIA? 🎥 Our page now features insightful videos explaining various roles at AQEMIA, giving you a glimpse behind the scenes of how we operate. Also, we are growing fast, already numbering around sixty, and we are recruiting for a wide range of positions to roll out our mission to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Below our COO & co-founder Emmanuelle Martiano Rolland discusses AQEMIA’s purpose and what differentiates us from other biotech companies. 🔗 Link to our Welcome to the Jungle page in the comments ⬇️ #welcometothejungle #AQEMIA #drugdiscovery #careeropportunities #biotech #hiring #MachineLearning #DrugHunter CC Marina Moisan Marion Birolini our HR stars🌟

🚀 Exciting milestone at AQEMIA! 🚀 We are thrilled to announce a research milestone on an undruggable target in immuno-oncology with Servier 🎉 In just months, leveraging our GenAI x Deep physics, we have identified a series of molecules active on this challenging target. This milestone highlights the immense potential of our unique GenAI x Deep physics platform for the discovery of innovative molecules 🧬. "Our teams are very proud of this achievement that demonstrates the power of AQEMIA's cutting-edge generative AI and deep physics in creating novel, patentable molecules to meet therapeutic needs that are still immense," said Maximilien Levesque, CEO & Co-founder of AQEMIA. Shoutout to Rose Hoste Marie-Hélène Fouchet Antoine Brochard for their exceptional contributions to this success! 🌟 🔗 Link to the press release in comment for more details. #drugdiscovery #pharma #genAI #quantumphysics #biotech #immunooncology #AQEMIA  Olivier Nosjean Veronique Blanc Bruno Laugel Chloé Leprêtre Christophe Meyer Wesley Blackaby Dave G Brown Claude Bertrand Virginie Martiny Zoltan Szlavic Maximilien Levesque Emmanuelle Martiano Rolland Orianne Bornand Nicolas Canouï Rose Hoste Marie-Hélène Fouchet Antoine Brochard

We are proud to share that AQEMIA is now part of the 120 most promising high-growth startups in France, selected by La French Tech through the FT120 based on criteria of fundraising and revenue 🚀 FT120 is a program by the French government to showcase the best of french tech, and we take this leadership role very much to heart 🇫🇷 Thanks La French Tech! Our journey has been remarkable, evolving from fundamental research at École normale supérieure-PSL in 2019 to joining the FT120 in 2024! Our technology, validated by leading pharmaceutical companies, recently led to a groundbreaking $140 million deal with Sanofi and a total of $60 million raised to date! 📣 👉 And because good news never comes alone, we're excited to invite you to join us at Viva Technology, starting tomorrow, on La French Tech and Sanofi booths to learn more about how AQEMIA is tackling these challenges and shaping the future of drug discovery. We look forward to connecting with you at Viva Technology! Maximilien Levesque Emmanuelle Martiano Rolland Bruno Le Maire Marina Ferrari Sylvie Retailleau Roland Lescure Clara Chappaz Nicolas Desruelles Bruno Bonnell Lise ALTER Nicolas Dufourcq Paul-François Fournier Alexis Auvitu Nicolas Canouï Théa Vu Marion Birolini #FT120 #FrenchTech #Vivatech2024 #Sanofi #AI #drugdiscovery #choosefrance

Thrilled to highlight AQEMIA in Le Figaro for pioneering AI in pharma with Sanofi. A special shoutout to Laurent Schio for his insights, highlighting the revolution of drug discovery by blending AI with existing pharmaceutical frameworks. #genAI #techpharma #molecules #deeptech Maximilien Levesque Emmanuelle Martiano Rolland Dr. Thomas Licher Matt Truppo Frank Nestle Houman Ashrafian Jean Philippe Rameau